Wednesday Oct 21 | BioSpace
CombinatoRx, Incorporated's Synavive (CRx-102) Maintains Efficacy...
CombinatoRx, Incorporated today announced the results of a 12 month knee osteoarthritis Phase 2 extension trial for Synavivea at the American College of Rheumatology 2009 Annual Meeting in Philadelphia.
Study examines treatment for olfactory loss after viral infection
Treatment with a glucocorticoid medication, either alone or in combination with Ginkgo biloba, appears to significantly improve the sense of smell in individuals with previous olfactory loss due to upper respiratory infections, according to a report in the October issue of Archives of Otolaryngology-Head & Neck Surgery .
Peoplea s Pharmacy: Hazards of rheumatoid arthritis drugs
Rheumatoid arthritis is a devastating disease. Besides crippling joints, it can leave the victim exhausted and in excruciating pain.
New England Journal of Medicine
A 28-year-old woman presented, and was admitted, to our hospital with a 2-day history of periumbilical postprandial abdominal pain with nausea and vomiting; she was receiving a maintenance regimen of low-dose prednisolone.
Allergy medications: Know your options
Allergy medications reduce your body's reaction to allergens or block symptom-causing chemicals such as histamine.
CombinatoRx Presents Full Data on Synavive Phase 2 Knee OA Trial at EULAR 2009
Jun 12, 2009 - CombinatoRx, Incorporated today announced the presentation of full data on Synavive Phase 2 knee osteoarthritis trial at EULAR 2009, the Annual European Congress of Rheumatology in Copenhagen on June 12, 2009.
CombinatoRx Announces Positive Results for Aligned-Release Synavive
Jun 3, 2009 - CombinatoRx, Incorporated today announced positive results from a Phase 1 clinical study evaluating the relative bioavailability of an oral once-daily aligned-release formulation of SynaviveTM .
Original Article: Steroid Control of Acute Middle Ear Inflammation in a Mouse Model
Carol J. MacArthur, MD ; Jacqueline M. DeGagne, BS ; J. Beth Kempton, BS ; Dennis R. Trune, PhD Objective To investigate steroids for their potential for therapeutic approaches to control otitis media.
"anybody have to be on category C medicine?"
I have to take these eye drops for my eye to keep them safe, Pred forte, nuvenac, and co-sopt, one is a steriod drop and one is an NSAID drop...they are all category C, and may or may not harm the baby and I am a little worried.
Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis
PARIS, May 4 Fovea-Pos-Results PARIS , May 4 /PRNewswire/ -- Fovea Pharmaceuticals announced today positive results from its clinical proof-of-concept trial to assess the therapeutic effect of Prednisporin in patients with persistent allergic conjunctivitis.
Sirion Therapeutics Announces Clinical Data Presentations At The 2009 ...
Main Category: Eye Health / Blindness Also Included In: Pharma Industry / Biotech Industry Clinical Trials / Drug Trials Sirion Therapeutics, Inc.
'Antedrugs': A safer approach to drug therapy
Corticosteroids are powerful drugs used to treat inflammatory conditions such as asthma and other chronic diseases which has made them among the most widely prescribed drugs.
Also on Topix